Gastric Emptying Recovery After GLP-1 RA Cessation
Key facts
- Who runs it
- Wonkwang University Hospital
- Where
- South Korea2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 186 people enrolled
- Started
- 20 Nov 2025
- Ended
- 12 Jan 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- Preoperative gastric ultrasound
- Record updated
- 23 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults aged ≥18 years
- Receiving a glucagon-like peptide-1 receptor agonist (GLP-1 RA)
- Scheduled for elective surgery under general anesthesia
- Able to provide written informed consent
Who cannot take part
- Prior gastric or esophageal surgery
- Emergency surgery
- Severe gastroesophageal reflux disease
- Known gastroparesis
- Pregnancy
- Inability to provide informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can delay gastric emptying and may increase residual gastric contents before general anesthesia. Current perioperative recommendations for withholding GLP-1 RAs (e.g., a fixed 7-day discontinuation for weekly agents) are largely consensus-based, and it is unclear whether gastric emptying normalizes abruptly after a single threshold interval. This prospective observational cohort study will evaluate how preoperative residual gastric content changes with increasing time since the last GLP-1 RA dose, using point-of-care gastric ultrasound performed immediately before induction of anesthesia. Time since last dose will be analyzed as a continuous exposure and across prespecified intervals (≤3 days, 4-7 days, ≥8 days). The primary outcome is ultrasound-estimated gastric volume normalized to body weight (mL/kg), derived from antral cross-sectional area. Secondary outcomes include the presence of a "high-risk stomach" based on gastric volume criteria and qualitative ultrasound findings. The study will also assess whether body mass index modifies the relationship between cessation interval and gastric volume, thereby supporting individualized perioperative risk assessment.
The 3 groups in the trial
- GLP-1 RA cessation ≤3 days
Participants using GLP-1 receptor agonists whose last dose was taken ≤3 days before the preoperative gastric ultrasound assessment (performed immediately prior to induction of anesthesia).
Treatment: Preoperative gastric ultrasound
- GLP-1 RA cessation 4-7 days
Participants using GLP-1 receptor agonists whose last dose was taken 4-7 days before the preoperative gastric ultrasound assessment (performed immediately prior to induction of anesthesia).
Treatment: Preoperative gastric ultrasound
- GLP-1 RA cessation ≥8 days
Participants using GLP-1 receptor agonists whose last dose was taken ≥8 days before the preoperative gastric ultrasound assessment (performed immediately prior to induction of anesthesia).
Treatment: Preoperative gastric ultrasound
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Time-dependent Recovery of Gastric Emptying After Cessation of Glucagon-like Peptide-1 Receptor Agonists: a Prospective Observational Gastric Ultrasound Study
- Record updated
- 23 January 2026